Pharmaceuticals
Study in rats finds long-term omeprazole use disrupts mineral levels linked to anemia and bone health risks
Raportoinut AI AI:n luoma kuva Faktatarkistettu
Researchers in Brazil report that prolonged use of the proton pump inhibitor (PPI) omeprazole altered iron and calcium measures in adult rats and shifted how several minerals were distributed across organs—changes they say are consistent with higher risks of anemia and possible bone health harms. The authors and Brazil’s health regulator stress that PPIs remain effective for acid-related disorders, but warn against extended, unsupervised use.
Collegium Pharmaceutical, Inc. (COLL) held an investor conference call on March 19, 2026, to discuss its acquisition of AZSTARYS and relevant corporate subsidiaries from Corium Therapeutics. The deal aims to expand the company's position in the ADHD market. Executives including CEO Vikram Karnani joined the call.
Raportoinut AI
Relmada Therapeutics, Inc. (RLMD) conducted its fourth quarter and full-year 2025 earnings conference call on March 19, 2026, at 4:30 PM EDT. The company released a press release detailing its business update and financial results for the periods ended December 31, 2025. Management highlighted forward-looking statements with associated risks.
Alkermes plc has published a slide deck accompanying its 2025 fourth-quarter earnings call. The materials were made available on February 25, 2026. This release provides insights into the company's financial performance for the period.
Raportoinut AI
Sarepta Therapeutics, Inc. conducted its fourth quarter 2025 earnings call on February 25, 2026. The company released its financial results earlier that day, with details available on its website. Executives including CEO Douglas Ingram participated in the discussion.
Egypt's Minister of Health and Population Khaled Abdel Ghaffar met Kazakhstan's ambassador to Egypt, Askar Zhenis, to discuss strengthening bilateral cooperation in healthcare and pharmaceutical manufacturing technology. Abdel Ghaffar emphasized Egypt's interest in expanding ties through the transfer of pharmaceutical manufacturing technologies and harmonizing Good Manufacturing Practice standards. The talks covered collaboration in pharmaceutical production, biotechnology, and public health initiatives.
Raportoinut AI
Chinese biotech firm SciNeuro Pharmaceuticals has partnered with Swiss pharmaceutical giant Novartis in a deal worth nearly $1.7 billion to develop treatments for Alzheimer's disease, which affects some 55 million people worldwide. The agreement grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro's antibody candidates for the progressive brain disease. SciNeuro's novel amyloid beta-targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross into the brain where Alzheimer's damage occurs.
Egypt steps up research cooperation with Takeda
10. maaliskuuta 2026 18.13Roche shares decline after giredestrant trial fails endpoint
5. maaliskuuta 2026 02.11Clara Foods develops world's first animal-free pepsin
2. maaliskuuta 2026 08.51Egypt unveils integrated plan to boost pharmaceutical and garments exports
1. maaliskuuta 2026 03.28Collegium Pharmaceutical publishes Q4 2025 earnings presentation
17. helmikuuta 2026 01.32Farmacias similares begins expansion to japan
14. helmikuuta 2026 10.20Egypt offers WHO-certified expertise to boost Africa's medicine production
5. helmikuuta 2026 16.06Japanese drugmakers slump after Trump unveils discount drug website
30. tammikuuta 2026 21.57Australian sepsis drug advances in human trial
17. tammikuuta 2026 13.01Delhi high court allows cheaper cancer drug in India